Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a report released on Monday,Benzinga reports. The brokerage currently has a $21.00 price target on the stock.

Several other equities analysts also recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a research report on Thursday, December 12th. HC Wainwright upped their price target on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a report on Thursday, December 12th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Trevi Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $9.31.

Trevi Therapeutics Stock Performance

TRVI opened at $4.51 on Monday. The stock’s 50 day moving average price is $4.10 and its 200-day moving average price is $3.43. Trevi Therapeutics has a one year low of $2.30 and a one year high of $5.05. The stock has a market cap of $346.67 million, a price-to-earnings ratio of -10.25 and a beta of 0.88.

Institutional Trading of Trevi Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in shares of Trevi Therapeutics by 220.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock valued at $336,000 after purchasing an additional 69,167 shares in the last quarter. Geode Capital Management LLC raised its stake in Trevi Therapeutics by 10.2% in the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock worth $4,223,000 after buying an additional 117,418 shares in the last quarter. Barclays PLC lifted its holdings in Trevi Therapeutics by 180.8% during the third quarter. Barclays PLC now owns 95,232 shares of the company’s stock worth $319,000 after buying an additional 61,317 shares during the period. State Street Corp boosted its position in Trevi Therapeutics by 5.9% during the 3rd quarter. State Street Corp now owns 952,912 shares of the company’s stock valued at $3,183,000 after acquiring an additional 53,051 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after acquiring an additional 6,764 shares during the period. 95.76% of the stock is owned by hedge funds and other institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.